Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIlika Plc Regulatory News (IKA)

Share Price Information for Ilika Plc (IKA)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 28.00
Bid: 27.00
Ask: 29.00
Change: 0.00 (0.00%)
Spread: 2.00 (7.407%)
Open: 28.00
High: 28.00
Low: 28.00
Prev. Close: 28.00
IKA Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

International Business Development Appointments

8 Oct 2010 10:30

RNS Number : 0953U
Ilika plc
08 October 2010
 



8 October 2010

Ilika plc

("Ilika" or the "Company" or the "Group")

Ilika expands its business development activities in the US and Asia

 

United States

Ilika is pleased to announce the appointment of the JGW Group ("JGW") to help develop new business opportunities primarily in the US aerospace and defence sectors. JGW, which is headquartered in Virginia, is well placed to access US Department of defence sites and has a proven track record of helping clients secure government contracts.

Alongside JGW, the Company announces the appointment of Stuardo Robles as a new business development director. Stuardo is a senior engineer and marketing professional with more than fifteen years of comprehensive business and technical leadership in manufacturing systems and related services in the global semiconductor industry, primarily with Applied Materials Inc.

Japan

Ilika has extended its relationship with Blue Rise Partners ("Blue Rise"). In addition to representing Ilika in the electronics and energy sectors, Blue Rise has appointed Takashi Matsui who will seek out opportunities for the company in the bio-medical sector.

Takeshi Ishikawa, business development director for Asia who has been with the company since 2005 and instrumental in the securing of a number of significant contracts, is relocating to Tokyo to spend more time addressing the increased interest that the Company is enjoying from Japanese multinationals.

Graeme Purdy, Ilika's CEO, commented, "These appointments significantly strengthen Ilika's ability to support its existing customer base and market its services to a much wider audience."

For more information contact:

Ilika plc

Graeme Purdy, Chief Executive

Steve Boydell, Finance Director

+44 (0) 23 80111400

 

Nomura Code Securities Limited

Phil Walker / Christopher Golden

+44 (0) 20 7776 1200

Pelham Bell Pottinger

Archie Berens / Olly Scott / Francesca Tuckett

 

+44 (0) 20 7861 3232

 

About Ilika

Ilika (AIM: IKA) is an advanced materials company which accelerates the discovery of new and patentable materials using its unique high throughput technologies (''HTT'') process for identified end uses in the energy, electronics and biomedical sectors. This process enables hundreds of scalable materials to be made in a single, automated operation and subsequently tested for key properties.

Traditionally, materials development has been a slow and arduous task, with manual, sequential methods used to make samples of material that are then tested for suitability. On average, it takes between seven and 10 years to move from an initial discovery through to the first commercial prototype. Experiments carried out by the Company can be executed 10 to 100 times faster than using traditional techniques.

The Company focuses on three principal sectors and has a number of active development programmes addressing markets within each sector:

Energy - developing innovative new materials for Lithium-ion batteries for vehicles for Toyota; developing high capacity hydrogen storage materials with Shell Hydrogen and Johnson Matthey through joint development programmes; developing cheaper alternatives to Platinum electrodes for use in fuel cells through a grant-funded project with the Carbon Trust; developing new materials for use in fuel cells for the transport sector for a major vehicle manufacturer; and carrying out in-house research on film photovoltaic solar cells.

Electronics - developing lead-free piezoelectric materials through a joint development programme with CeramTec; and developing phase change memory materials for high capacity memory.

Biomedical - developing polymers to enable the filtering of somatic stem cells from blood with a major global supplier of filters; it has been selling its CryoSkin® and MySkin® products for the treatment of burns and wounds in the UK through a specialist distributor and intends to commence clinical trials of its corneal bandage candidate.

The Group's commercialisation strategy is to enter into joint development or licensing agreements with large multinational companies which are seeking to commercialise products developed using the intellectual property created through jointly-funded programmes. Current commercialisation partners include large multinational companies such as Toyota, Shell, Johnson Matthey and CeramTec. The Company generates revenues from three sources: licensing and milestone payments from joint development programmes; fee for service from contract research projects; and from sales of CryoSkin® and MySkin®.

www.ilika.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAGCBDGUDGBGGI
Date   Source Headline
12th Nov 20137:00 amRNSHalf Year Trading Update
28th Oct 20137:00 amRNSIlika expands into Aerospace Sector
21st Oct 20137:00 amRNSInvestor Teach-in
17th Sep 20134:09 pmRNSResult of AGM
17th Sep 20137:00 amRNSAGM Statement
16th Sep 20137:00 amRNSTwo New Customers in Europe
23rd Aug 20131:25 pmRNSPosting of Annual Report & Notice of AGM
2nd Aug 20135:02 pmRNSConversion of Securities
30th Jul 20137:00 amRNSContract Renewals and Grant Award
19th Jul 20132:50 pmRNSHolding(s) in Company
19th Jul 201311:17 amRNSHolding(s) in Company
18th Jul 20137:00 amRNS£3.3 million EPSRC Grant Award to Southampton Univ
15th Jul 20137:00 amRNSFinal Results
21st May 20131:09 pmRNSHolding(s) in Company
20th May 20137:00 amRNSDirectorate Change and Conversion of Securities
17th May 20133:57 pmRNSPlacing - Replacement
17th May 20137:00 amRNSPlacing
1st May 20137:00 amRNSFuel Cell Catalyst Patent Granted in Japan
22nd Apr 20137:00 amRNSContract with new European Customer
16th Apr 20137:00 amRNSTrading Update
21st Feb 20137:00 amRNSRenewal of Contract
29th Jan 20137:00 amRNSCompletion of Laboratory Facility Expansion
18th Jan 20133:28 pmRNSHolding(s) in Company
17th Jan 20135:46 pmRNSHolding(s) in Company
17th Jan 201311:16 amRNSHolding(s) in Company
15th Jan 20135:21 pmRNSHolding(s) in Company
10th Jan 20137:00 amRNSInterim Results
21st Dec 20127:00 amRNSGrant of Fuel Cell Catalyst Patent
18th Dec 20121:41 pmRNSCompletion of Disposal
17th Dec 20127:00 amRNSConversion of Securities
11th Dec 20127:00 amRNSRenewal of Contract
29th Nov 20124:44 pmRNSHolding(s) in Company
28th Nov 20125:00 pmRNSHolding(s) in Company
27th Nov 20122:18 pmRNSHolding(s) in Company
19th Nov 20127:00 amRNSEnergizer Relationship Update
22nd Oct 20127:00 amRNSTrading Update
5th Oct 20127:00 amRNSHolding(s) in Company
5th Oct 20127:00 amRNSTotal Voting Rights
18th Sep 20127:00 amRNSDiscontinuing of wound care products and services
14th Sep 20127:00 amRNSCarbon Trust Investment
7th Sep 20121:27 pmRNSResult of AGM
7th Sep 20127:00 amRNSAGM Statement
9th Aug 20127:00 amRNSPosting of Annual Report & Notice of AGM
19th Jul 20127:00 amRNSFinal Results
14th Jun 20127:14 amRNSChange of Adviser
1st Jun 201210:01 amRNSTotal Voting Rights
18th May 20127:00 amRNSTrading Update
17th May 20127:00 amRNSConversion of Securities
2nd May 20127:00 amRNSVapour Deposition Method US Patent Grant
1st May 20123:00 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.